MenQuadfi

Meningococcal group A, C, W & Y conjugate vaccine

Active immunisation of individuals ≥12 mth against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, & Y.

IM Primary vaccination Individual ≥12 mth 0.5 mL single dose. A single 0.5 mL dose may be used to boost subjects who have previously received a meningococcal vaccine containing the same serogroups.

Hypersensitivity.

Should not be administered SC, intravascularly or intradermally. Appropriate medical treatment & supervision should always be readily available in case of an anaphylactic event following vaccine administration. Postpone vaccination in individuals suffering from an acute severe febrile illness. Risk of syncope & other anxiety-related reactions as a psychogenic response to the needle inj. Caution in individuals w/ thrombocytopenia or any coagulation disorder. MenQuadfi will only protect against Neisseria meningitidis groups A, C, W, & Y; it will not protect against any other Neisseria meningitidis groups. Consider risk of MenA infection in high-risk individuals who received serogroup C meningococcal conjugate vaccine in the 1st yr of life. Adequate immune response may not be elicited in patients receiving immunosuppressive treatment or patients w/ immunodeficiency. Not a substitute for routine tetanus immunisation. Pregnancy & lactation. Safety & immunogenicity of MenQuadfi in individuals <12 mth have not yet been established.

Inj site tenderness/pain, swelling & erythema, fever. Individuals ≥2 yr: Headache; myalgia; malaise. Individuals 12-23 mth: Appetite lost; irritability; drowsiness; abnormal crying; vomiting, diarrhoea.

Adequate immune response may not be elicited in patients receiving immunosuppressives. Consider separate administration of MenQuadfi & 13-valent pneumococcal polysaccharide conjugated vaccine in childn 12-23 mth at high risk for serogroup A disease.

Vaccines, Antisera & Immunologicals

J07AH - Meningococcal vaccines ; Used for active immunizations.

P₁S₁S₃